AYUSH 82 powder is an Ayurvedic antidiabetic formulation developed by the Central Council for Research in Ayurvedic Sciences (CCRAS), Ministry of AYUSH, Government of India. It comprises ingredients traditionally used for their beneficial effect in diabetes (Prameha/Madhumeha). The hypoglycemic effects of AYUSH 82 powder have been reported in diabetic subjects. In the current study, the antidiabetic potential of AYUSH 82 powder along with its two new dosage forms -AYUSH 82 mixture extract and AYUSH 82 compound extractwas investigated in vitro for elucidating mechanism of their action by possible α-amylase inhibitory property, insulindependent glucose uptake in skeletal muscle cell line (C2C12 myotubes), and effect on peroxisome proliferator-activated receptor gamma (PPAR-γ) activity.
INTRODUCTION
The prevalence of diabetes mellitus in India is predicted to double from 171 million in 2000 to 366 million in 2030, posing a significant health care burden. 1 The major concern regarding this observation relates to the development of chronic complications associated with the condition, either microvascular -retinopathy, nephropathy, and neuropathy -or macrovascular -cardiovascular disease, cerebrovascular accidents, and peripheral vascular disease. 2 It is well recognized that these complications cause considerable morbidity and mortality worldwide and, as such, negatively an increase in disability and death. 3 The costs of caring for diabetes and its related complications are also staggering. The estimated financial burden of diabetes was US$174 billion in 2007 and it is expected to be US$330 billion by 2020 due to the expected increase in new cases in the United States alone. In India, diabetes care can cost low-income households about one-third of their incomes. 4, 5 Providers caring for patients with diabetes recognize that the patients are very interested in alternative supplementation and may choose to supplement their pharmacological regimen with supplementation popularly from natural products, i.e., herbal or botanical sources. 6 From the patient perspective, it is considered very acceptable to include herbal or botanical extracts as part of the medical intervention based on the recognition that the herbal intervention is considered to be natural and that the practice may have been part of the culture for many generations. However, currently, there is a paucity of consistent and reproducible efficacy data in humans to suggest any recommendations for most botanical or bioactive supplements as adjunct treatments for risk factors related to type II diabetes. Firm recommendations for general use would also require an understanding of the mechanism of action, which is not known for most botanicals. 4 AYUSH 82 is an Ayurvedic hypoglycemic formulation developed by the Central Council for Research in Ayurvedic Sciences (CCRAS), Ministry of AYUSH, Government of India. It comprises ingredients traditionally used for their beneficial effect in diabetes (Prameha/ Madhumeha). 7 Glucose-lowering effects of AYUSH 82 powder have been reported in patients of Madhumeha
[noninsulin-dependent diabetes mellitus (NIDDM)] where AYUSH 82 powder (5 gm thrice a day with 500 mg of pure Shilajita twice a day) was found to significantly reduce fasting and postprandial blood sugar levels along with clinical improvement in diabetic subjects after 24 weeks of treatment. 8 In another clinical study, AYUSH 82 administered at similar doses to patients of NIDDM was found to produce significant reduction (p > 0.001) in both fasting and postprandial blood sugar and marked decrement in symptoms of diabetes like polyuria, polydipsia, polyphagia, weakness, and exhaustion after a treatment period of 6 weeks. 9 In the current study, we investigated the antidiabetic potential of AYUSH 82 powder along with two new dosage forms -the mixture extract and the compound extract -through their mechanism of action. All the three dosage forms were investigated for possible α-amylase inhibitory property, insulin-dependent glucose uptake in skeletal muscle cell line (C2C12 myotubes), and effect on peroxisome proliferator-activated receptor gamma (PPAR-γ) activity through in vitro assays.
MATERIALS
AYUSH 82 powder was developed by the CCRAS, Ministry of AYUSH, Government of India, for the management of type II diabetes. For the current studies, AYUSH 82 powder and its extracts were procured from M/s Dabur India Ltd., Ghaziabad, Uttar Pradesh, India under technical knowhow from the CCRAS. The composition details of AYUSH 82 are given in Table 1 .
Preparation of AYUSH 82 Mixture Extract and Compound Extract
Hydroalcoholic extraction of herbs (Karvellaka, Jamun, Amra, Gurmar) was done. The extract was concentrated and dried to fine powder, which was checked for compliance with specification parameters. For AYUSH 82 mixture extract, equal quantities of herbs were extracted individually and then mixed. For AYUSH 82 compound extract, the herbs were mixed together in equal proportions and then extracted. 
For PPAR-γ Activity
The DMSO (Merck), Rosiglitazone (Sigma), Substrate Loading Solution consisted: Solution A (10 mM LiveBLAzer™-FRET B/G Substrate), Solution B, and Solution C (Life Technologies).
METHODS

Inhibition of α-Amylase Activity
The inhibitory potential of the three test items (TIs) on activity of α-amylase was evaluated using in vitro cell-free enzyme-based assay in comparison to positive controls -acarbose and quercetin. 10, 11 Amylase activity was determined by starch-iodine method using starch as a substrate and measuring the dextrinizing activity of amylase in terms of decrease in the color of iodine. 12, 13 Absorbance of samples was read at 620 nm.
Preparation of TIs
Aqueous Formulation
Test items were weighed and dissolved in MilliQ water to prepare stock solution of 250 mg/mL. This stock solution was diluted in 20 mM phosphate buffer to prepare final concentrations ranging from 10 μg/mL to 20 mg/mL.
Methanolic Formulation
Test items were weighed and dissolved in methanol to prepare stock solution of 250 mg/mL. This stock solution was diluted in methanol to prepare final concentrations ranging from 50 μg/mL to 25 mg/mL. 
JDRAS
Phosphate Buffer
To make 0.2 M monobasic stock, 2.4 gm sodium phosphate monobasic (NaH 2 PO 4 ) was dissolved in 100 mL of MilliQ water. To make 0.2 M dibasic stock, 2.84 gm sodium phosphate dibasic anhydrous (Na 2 HPO 4 ) was dissolved in 100 mL of MilliQ water. To prepare 0.1 M phosphate buffer (pH 6.9), 45 mL of monobasic stock and 55 mL of dibasic stock were mixed and final volume was adjusted to 200 mL with MilliQ water. This 0.1 M phosphate buffer was diluted to prepare 20 mM phosphate buffer (pH 6.9).
Starch Solution (1%)
Starch 200 mg was weighed and dissolved in 20 mL of 20 mM phosphate buffer. This solution was heated at 40 to 50°C with constant stirring till a clear solution was obtained.
Iodine Solution (5 mM)
Potassium iodide (KI) 42 mg was dissolved in 50.602 mL of MilliQ water; 5 mM iodine solution: 64 mg iodine was dissolved in 50.394 mL of 5 mM KI solution. This solution was used as iodine solution for termination of the reaction. α-Amylase weighing 11 mg was weighed and dissolved in 14.667 mL 20 mM phosphate buffer to obtain a stock of 0.75 mg/mL.
Positive Control-1 (Acarbose)
Acarbose 4 mg was weighed and dissolved in MilliQ water to prepare 1 gm/mL stock solution. This stock solution was diluted using phosphate buffer to achieve final concentrations of 20, 60, 80, and 100 mg/mL.
Positive Control-2 (Quercetin)
Quercetin 4 mg was weighed and dissolved in DMSO to prepare 1 gm/mL stock solution. This stock solution was diluted using phosphate buffer to achieve final concentration of 10 mM.
Amylase Enzyme Inhibition Assay
Test items of 75 μL at final concentrations (10 μg/mL to 20 mg/mL for aqueous formulation and 50 μg/mL to 25 mg/mL for methanolic formulation respectively) were preincubated with 50 μL of α-amylase solution (0.75 mg/mL) prepared in phosphate buffer in a total volume of 500 μL for 15 minutes at 25°C. Test items at different concentrations in the absence of enzyme were taken as blanks in a total volume of 500 μL. The 50 μL of enzyme alone treated with buffer in a total volume of 500 μL was taken as control for aqueous formulations; 50 μL of enzyme alone treated with 75 μL of methanol in a total volume of 500 μL was taken as control sample for methanolic formulations. The reaction was initiated by adding 250 μL of substrate (1% starch solution). The reaction mixture was incubated for 30 minutes at 25°C. The reaction was terminated by addition of 0.2 mL of 1 M HCl and 1 mL of iodine solution. The activity of amylase was determined by measuring the absorbance at 620 nm and is inversely proportional to color of the reaction. The inhibitory effect of TIs on α-amylase activity was determined as percent decrease in the enzyme activity with respect to control sample. Percent enzymatic activity of α-amylase was calculated as follows:
Percent inhibition of α-amylase activity was calculated as:
Enzymatic activityin Test Item treatedsample −
Evaluation of Antidiabetic Potential of Various Herbal Formulations using Mouse Skeletal Muscle Cell Line (C2C12 Myotubes) in vitro
The study was conducted to determine the effects of different dosage forms of AYUSH 82 on skeletal muscle glucose metabolism utilizing insulin-dependent glucose uptake in mouse skeletal muscle cell line (C2C12 Myotubes).
14 Noncytotoxic concentration of DMEM + 10% FBS was used as positive control for validation of the assay. It was dissolved in 10% serum-free medium to obtain 10% working concentration range. Glucose uptake was studied utilizing insulin (200 nM). Stock solution of 100 mg/mL of insulin was prepared utilizing 50% methanol as solvent to obtain working concentration range of 1 μg/mL to 1 mg/mL (noncytotoxic concentrations) and 10 μg/mL to 1 mg/mL (for glucose uptake).
15,16
Differentiation of Skeletal Muscle C2C12 Myoblasts to Myotubes
The skeletal muscle cell line, C2C12 myoblasts, was maintained in DMEM supplemented with 10% FBS at 37°C at 5% CO 2 . After reaching confluency, cells were induced to differentiate from myoblasts to myotubes. To induce differentiation, growth medium was replaced with DMEM containing 1% FBS. Myoblasts were differentiated into myotubes after 10 days of daily medium change (DMEM + 0.1% FBS medium). Experiments were performed on differentiated C2C12 myotubes.
Determination of Noncytotoxic Concentrations of TIs on C2C12 Myotubes
The cells were trypsinized and a single-cell suspension was obtained. The cell suspension was counted on a hemocytometer. The cells were seeded at a density of 10 × 10 3 cells/well in 96-well plate. The seeded plate was incubated overnight at 37°C in a 5% CO 2 incubator. Subsequent to incubation, skeletal muscle C2C12 myoblasts were differentiated to myotubes and treated with different concentrations of TIs ranging from 1 μg/mL to 1 mg/ mL in triplicates. 18 Subsequently, treated cells were incubated for a time period of 24 hours at 37°C in a 5% CO 2 incubator. The untreated cells were used as controls. After treatment of C2C12 myotubes with TIs at concentrations ranging from 1 μg/mL to 1 mg/mL for a time period of 24 hours at 37°C in a 5% CO 2 incubator, the viability of the cells were determined by 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide (MTT)-based assay. A total of 20 μL of 5 mg/mL of MTT was added to all the wells and incubated for 3 hours at 37°C in a 5% CO 2 incubator. Subsequent to incubations, the supernatant was aspirated without disturbing the formazan complex and 150 μL of DMSO was added to all wells to dissolve the formazan crystals.
The optical density of each well was read at 540 nm on a multiplate Biotek reader. Noncytotoxic concentrations of TIs were determined by calculating percent viability of C2C12 myotubes as follows:
where X = OD of cells treated with TI(s); R = OD of untreated control cells.
Glucose Uptake
C2C12 myoblasts were plated in 48-well plate at a density of 30 × 10 3 cells per well and incubated overnight at 37°C in 5% CO 2 incubator after which they were differentiated with predetermined noncytotoxic concentrations of TIs ranging from 10 μg/mL to 1 mg/mL and insulin (200 nM). The treated cells were incubated for 24 hours at 37°C in 5% CO 2 incubator. Following the incubation period, these were washed twice with phosphate-buffered saline (PBS; pH 7.4) and were incubated for 30 minutes at 37°C in PBS (pH 7.4). Subsequent to incubation, C2C12 myotubes were washed twice with PBS (pH 7.4) at 37°C.
A total of 450 μM of 2-[N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl) amino]-2-deoxy-D-glucose (2-NBDG) prepared in PBS (pH 7.4) was added to all the wells and incubated for 30 minutes at 37°C. Cells were lysed by freeze thaw in PBS (pH 7.4). Fluorescence of 2-NBDG were measured in cell lysates using multiplate Biotek reader at an emission wavelength of 528 nm and excitation wavelength of 485 nm. [17] [18] [19] Percentage increase in the glucose uptake by the TI(s)-treated cells as compared with control untreated cells was calculated as follows:
where X = Fluorescence of cells treated with TI(s); R = Fluorescence of untreated control cells.
Determination of Noncytotoxic Concentrations of TIs on C2C12 Myotubes
Criterion for evaluation of noncytotoxic concentrations was cell viability ≥70% as compared with control cells. All the TIs were found to be noncytotoxic at concentrations ranging from 1 μg/mL to 1 mg/mL for 24 hours on C2C12 myotubes and safe to use for further evaluation of antidiabetic potential of TIs.
Effect on PPAR-γ Activity using in vitro Assay
The study was conducted to evaluate the effect of TIs on PPAR-γ expression, for their antidiabetic potential in vitro utilizing cell-based assays. UAS-bla HEK 293H cell line containing the ligand-binding domain of the human PPAR-γ was treated with TIs for 24 hours at different concentration ranges. The activation of PPAR-γ expression was monitored by fluorescence-based assay. 20 
Preparation of Stock Solution
The DMSO stocks of TI were prepared (AYUSH 82 powder and mixture -extract 50 mg/mL; AYUSH 82 compound extract -100 mg/mL), which were treated as 1,000× stock solution. These were serially diluted (10 point ½-log increments) in 100% DMSO to obtain final tested concentrations of 0.0015 μg/mL to 50 μg/mL for TI 1 and 2 and 0.003 μg/mL to 100 μg/mL for TI 3. A total of 40 nL of 1,000× test compound or known activator [4 μL of a 10× serial dilution of rosiglitazone (positive control agonist starting concentration, 316 nM)] plus 4 μL of assay media was added to 384-well poly-D-lysine assay plate.
21,22
The PPAR-γ-UAS-bla HEK 293H cells were thawed and resuspended in assay media (DMEM phenol red free, 2% CD-treated FBS, 0.1 mM NEAA, 1 mM sodium pyruvate, 100 U/mL/100 μg/mL Pen/Strep) to a concentration of 937,500 cells/mL. A total of 32 μL of cell suspension (30,000 cells) was added to each well; 4 μL of assay media was added to all wells to bring the final assay volume to 40 μL. The plate was incubated for 24 hours at 37°C/5% CO 2 in JDRAS a humidified incubator; 8 μL of 1 μM substrate loading solution was added to each well and the plate was incubated for 2 hours at room temperature. The assay plate was read on a fluorescence plate reader (Tecan Safire2) and the data were analyzed for percent activation. Vehicle (DMSO)-treated cells were used as control.
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RESULTS
Effect on α-Amylase Activity
Aqueous formulations of AYUSH 82 mixture extract and AYUSH 82 compound extract and the methanolic formulations of all the three dosage forms of AYUSH 82 demonstrated inhibitory effect on α-amylase activity in a dose-dependent manner, indicating the antidiabetic potential. AYUSH 82 mixture extract demonstrated highest extent of inhibition of α-amylase activity in both aqueous (48.2%) and methanolic (87.4%) formulations at concentration of 20 and 25 mg/mL respectively (Tables 2  and 3 ; Graphs 1 and 2).
Glucose Uptake in Skeletal Muscle Cell Line (C2C12 Myotubes)
All the TIs at tested concentrations (10 μg/mL, 50 μg/mL, 100 μg/mL, 500 μg/mL, and 1 mg/mL) showed increase in glucose uptake by the skeleton muscle cell line (C2C12 myotubes) as compared with control. Insulin (positive control) at a concentration of 200 nM demonstrated 137% increase in glucose uptake as compared with control, indicating potential antidiabetic activity (Table 4 ; Graph 3).
Effect on PPAR-γ Activity
There was no activation of PPAR-γ as compared with vehicle control (DMSO) by any of the TIs in the tested concentration range. Positive control (rosiglitazone) demonstrated strong activation of PPAR-γ with an IC50 of 3.15 nM.
DISCUSSION
Natural α-amylase inhibitors of herbal origin are an attractive therapeutic approach to control postprandial hyperglycemia via reducing the glucose release from starch and delaying carbohydrate absorption. These compounds are able to inhibit the activity of the carbohydrate hydrolyzing enzymes in the small intestine and are potentially useful in control of diabetes. 24 Results of the current study indicate that methanolic formulations of all the three dosage forms of AYUSH 82 -powder, the mixture extract, and the compound extract -could inhibit α-amylase activity in a dose-dependent manner. AYUSH 82 mixture extract, however, demonstrated highest extent of inhibition in both aqueous (48.2%) and methanolic (87.4%) formulation. Skeletal muscle is one of the major insulin-target tissues responsible for the maintenance of whole body glucose homeostasis and accounts for the bulk of insulinstimulated glucose disposal (70-80%) after a meal. 21 Insulin and exercise play central roles in the regulation of glucose transport and its metabolism in the muscles. The maintenance of glucose homeostasis is critical for normal physiology, and any alteration of blood glucose levels directly affects a variety of insulin actions. For example, in chronic hyperglycemia, the predominant metabolic state of diabetes can exacerbate defective glucose disposal by interfering with insulin action in insulin-target tissues, including skeletal muscle. 21 In the current study, all the three dosage forms of AYUSH 82 at tested concentrations (10 μg/mL, 50 μg/mL, 100 μg/mL, 500 μg/mL, and 1 mg/mL) showed an increase in glucose uptake by the skeleton muscle cell line (C2C12 myotubes) as compared with control. AYUSH 82 compound extract, however, showed maximum increase in glucose uptake in a dose-dependent manner (112% increase at concentration of 1 mg/mL). The PPAR-γ has been the focus of intense research during the past decade because ligands for this receptor have emerged as potent insulin sensitizers used in the treatment of type II diabetes. Agonists of the nuclear receptor PPAR-γ (thiazolidinediones) are therapeutically used to combat hyperglycemia associated with the metabolic syndrome and type II diabetes. 25 The effect of all the three dosage forms of AYUSH 82 was also studied on PPAR-γ expression as many natural products are reported to have PPAR-γ activating potential. Results of the current study, however, demonstrated that none of the TIs exhibited activation of PPAR-γ expression in tested ranges, indicating that antidiabetic potential of tested AYUSH 82 may not be mediated via PPAR-γ activation but by other mechanisms.
CONCLUSION
All the tested dosage forms of AYUSH 82 -powder, mixture extract, and the compound extracts -showed potential antidiabetic activity mediated either through inhibition of α-amylase or regulation of insulin-dependent glucose uptake in mouse skeletal muscle cell line. However, none of the three dosage forms of AYUSH 82 exhibited activation of PPAR-γ expression in tested ranges, indicating that antidiabetic potential of tested AYUSH 82 may not be mediated via PPAR-γ activation.
In conclusion, all the three formulations (AYUSH 82 powder, mixture extract, and the compound extract) have shown antidiabetic activity though inhibition of α-amylase activity or regulation of insulin-dependent glucose uptake in mouse skeletal muscle cell line. Out of the three, the AYUSH 82 mixture extract demonstrated highest extent of inhibition of α-amylase activity while the compound extract showed highest insulin-dependent glucose uptake in muscles. These new formulations (mixture extract and compound extract) may be useful for making new dosage forms of AYUSH 82 as tablets/ capsule. 
